ExeVir pulls in $50m Series A
ExeVir, a developer of single domain antibody therapies, has raised $50 million in Series A financing.
ExeVir, a developer of single domain antibody therapies, has raised $50 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination